Company profile
CEN Biotech, Inc.
OTC: CENBF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Windsor, ONCIK 0001653821Reports USD
#913 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ 17GM —SS 18
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, Piotroski F · ↓ market scale, workforce scale
Methodology →Revenue TTM
$619.8k
Rev growth YoY (TTM)
-54.9%
Net income (FY)
-$18.9M
Employees
4
as of 2026-08-30
Market cap
$6.5k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$626.9k$626.9k2021
Net income-$18.9M-$18.9M2021
Operating income-$19.0M-$19.0M2021
Total assets$8.4M$8.4M2021
Liabilities$10.1M$10.1M2021
Equity-$1.7M-$1.7M2021
Revenue trend
FY2016 – FY2021 · USD
FY16
FY17
FY21
FY21
Revenue by segment
Filed disclosures · FY2021
By product
Digital100%
Growth0%
By geography
Not disclosed.
The read
What is CEN Biotech, Inc.’s revenue?
CEN Biotech, Inc. booked $626.9k in FY2021 revenue — among the slowest-growing Healthcare companies we track, at a -3015.6% net margin.
Peers · Healthcare
Marizyme, Inc.——BioXcel Therapeutics, Inc.27DComera Life Sciences Holdings, Inc.——Co-Diagnostics, Inc.33DNovelStem International Corp.37DTheralink Technologies, Inc.——Key facts
CEOBrian S. Payne
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersWindsor, ON
ExchangeOTC: CENBF
Employees4
IPO date2020-05-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.